SERS liquid biopsy: An emerging tool for medical diagnosis

• Published in: Colloids and surfaces, B, Biointerfaces Vol. 208; p. 112064
• Main Authors: Moisoiu, Vlad, Iancu, Stefania D., Stefancu, Andrei, Moisoiu, Tudor, Pardini, Barbara, Dragomir, Mihnea P., Crisan, Nicolae, Avram, Lucretia, Crisan, Dana, Andras, Iulia, Fodor, Daniela, Leopold, Loredana F., Socaciu, Carmen, Bálint, Zoltán, Tomuleasa, Ciprian, Elec, Florin, Leopold, Nicolae
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01-12-2021
• Subjects: Carotenoids; Proteins; Purine metabolites; SERS liquid biopsy; Surface-enhanced Raman scattering; Proteins; SERS liquid biopsy; Carotenoids; Purine metabolites; Surface-enhanced Raman scattering
• ISSN: 0927-7765; 1873-4367
• DOI: 10.1016/j.colsurfb.2021.112064

[Display omitted]
•Surface-enhanced Raman spectroscopy (SERS) is an emerging tool for liquid biopsy.•Purine metabolites, proteins and carotenoids can be simultaneously detected by SERS.•SERS detects metabolic changes associated with cellular turnover rate, inflammation and antioxidant activity.
Surface-enhanced Raman scattering (SERS) is emerging as a novel strategy for biofluid analysis. In this review, we delineate four experimental SERS protocols that are frequently used for the profiling of biofluids: 1) liquid SERS for the detection of purine metabolites; 2) iodide-modified liquid SERS for the detection of proteins; 3) dried SERS for the detection of both purine metabolites and proteins; 4) resonant Raman for the detection of carotenoids. To explain the selectivity of each experimental SERS protocol, we introduce a heuristic model for the chemisorption of analytes mediated by adsorbed ions (adions) onto the SERS substrate. Next, we show that the promising results of SERS liquid biopsy stem from the fact that the concentration levels of purine metabolites, proteins and carotenoids are informative of the cellular turnover rate, inflammation, and oxidative stress, respectively. These processes are perturbed in virtually every disease, from cancer to autoimmune maladies. Finally, we review recent SERS liquid biopsy studies and discuss future steps that are required for translating SERS in the clinical setting.